Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma

2.1 Brexucabtagene autoleucel (Tecartus, Kite) is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after 2 or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The price was submitted as commercial in confidence. The company has a commercial arrangement. This makes treatment with brexucabtagene autoleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.